Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for ...

Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/27.eIlyUyvL.js ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...

New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the ...